The Unmet Need in Type 1 Diabetes Care

Type 1 diabetes (T1D) remains one of the most demanding chronic conditions to manage. Unlike type 2 diabetes, where the body still produces some insulin, T1D results from an autoimmune destruction of the pancreatic beta cells. This leaves patients completely dependent on exogenous insulin—delivered via multiple daily injections or continuous subcutaneous insulin infusion pumps. Despite advances in insulin analogs and continuous glucose monitoring (CGM), achieving stable euglycemia is elusive for the majority of patients. Glycemic variability, hypoglycemic unawareness, and the constant burden of carbohydrate counting and dose adjustment degrade quality of life. Even with the most sophisticated hybrid closed-loop systems, the underlying biology is not restored. This is why the Juvenile Diabetes Research Foundation (JDRF) has prioritized the development of a bioartificial pancreas (BAP)—a device that restores physiological insulin secretion by housing living insulin-producing cells in an immunoprotective scaffold.

What Is a Bioartificial Pancreas?

A bioartificial pancreas is not a single device but a class of emerging therapies that combine cellular therapy with materials science. The core concept involves transplanting insulin-producing cells—either from donor islets, stem cell-derived beta cells, or genetically engineered cells—within a semipermeable membrane or hydrogel. This membrane allows oxygen, nutrients, glucose, and insulin to diffuse freely while shielding the cells from the host immune system, thereby eliminating or reducing the need for systemic immunosuppression. JDRF has long recognized that a fully functional BAP must meet several criteria: long-term cell viability, rapid glucose sensing and insulin secretion, adequate vascularization, and resistance to fibrosis. The JDRF's strategic investment portfolio targets each of these challenges simultaneously.

JDRF’s Strategic Framework for BAP Development

Funding the Science: From Bench to Bedside

JDRF operates with a venture philanthropy model, providing grants and milestone-based funding to academic labs and startups. Unlike standard NIH grants, JDRF often funds high-risk, high-reward projects that industry may overlook. Through the JDRF Research Program, they have committed hundreds of millions of dollars toward bioartificial pancreas technology. Notable initiatives include the Encapsulation Consortium, a multi-institutional collaboration aimed at standardizing materials and testing protocols. Researchers at the University of California San Diego, Harvard’s Wyss Institute, and the Diabetes Research Institute in Miami have all received JDRF support to refine cell encapsulation techniques.

Encapsulation Technologies: Macroencapsulation vs. Microencapsulation

One of the most critical decisions in BAP design is the encapsulation format. JDRF-funded studies explore both macroencapsulation—where cells are packed into a larger planar or cylindrical device—and microencapsulation, where individual cells or small clusters are coated in a thin polymer shell. Macrodevices offer easier retrievability but suffer from limited oxygen diffusion in their core. Microbeads enhance surface-to-volume ratio but may be difficult to implant and retrieve en masse. JDRF has supported head-to-head comparisons using the Immunoisolation Core at the University of Alberta, providing researchers with standardized protocols to evaluate capsule performance in non-human primate models.

Stem Cell-Derived Beta Cells: The Unlimited Supply

For a bioartificial pancreas to become a transformative therapy, the cell source must be scalable and consistent. JDRF has been a cornerstone funder of the Human Islet and Stem Cell Research portfolio. Through partnerships with ViaCyte (now Vertex), Sernova, and the Harvard Stem Cell Institute, JDRF helped advance the differentiation of human pluripotent stem cells into functional, glucose-responsive beta cells. The STAPLE trial (Short Term Assessment of PEC-Direct in Patients) and the PEC-Encap studies are direct outcomes of this investment. These clinical trials have demonstrated that stem cell-derived cells can survive and secrete insulin in patients for months, albeit with partial immunosuppression in some arms. JDRF continues to fund next-generation cell lines that are hypoimmunogenic—engineered to evade not only the adaptive immune system but also the innate immune response.

Overcoming the Oxygen Barrier

Perhaps the most vexing challenge for any implantable cell device is oxygen. Pancreatic islets are highly metabolically active and require a robust oxygen supply to function. Inside a dense macrodevice or a thick encapsulant, cells quickly succumb to hypoxia. JDRF has funded multiple approaches to solve this problem. The βAir device, developed by the Swedish company CellMax, integrates an internal oxygen reservoir that is recharged daily via a percutaneous port. Early JDRF-supported trials in Gothenburg showed that the βAir device maintained human islet viability for over six months in diabetic rodents. Another approach, championed by the JDRF-funded team at MIT, uses photosynthetic algae or engineered red blood cells embedded in the device scaffold to generate oxygen in situ. While still preclinical, these strategies illustrate JDRF’s willingness to explore unconventional biology.

Immune Evasion Without Drugs

A bioartificial pancreas that requires lifelong immunosuppression would not be a true breakthrough. JDRF has therefore made immune evasion a central pillar of its BAP roadmap. Alongside physical encapsulation, the foundation supports the development of immune-modulating biomaterials that locally suppress cytokine release or T-cell activation. For example, researchers at the University of Michigan, funded by JDRF, are testing hydrogels that slowly release rapamycin or CTLA4-Ig at the implant site. Others are engineering the cells themselves to express immune checkpoint ligands like PD-L1, as seen in the work of Dr. Matthias Hebrok’s lab at UCSF (supported by JDRF). This dual strategy—physical barrier plus local immunomodulation—may achieve the holy grail: long-term graft survival without systemic side effects.

Clinical Trials and Regulatory Pathways

JDRF’s Role in Accelerating Translation

JDRF does not stop at basic science. The organization’s Translational Development Team works directly with the FDA and EMA to define clear regulatory pathways for BAPs. Since a bioartificial pancreas is a combination product (drug + device + biologic), it requires complex regulatory alignment. In 2020, JDRF co-hosted a public workshop with the FDA on cellular therapy for diabetes, which directly shaped the agency’s draft guidance on encapsulated cell products. This effort has reduced uncertainty for developers and shortened the time from preclinical proof-of-concept to first-in-human studies.

Landmark Clinical Data from JDRF-Supported Studies

Several trials deserve mention. The EctoCell® macroencapsulation device (from IsletOne Inc.) received JDRF funding for a Phase I/II study that demonstrated C-peptide production in five of eight patients at six months, with no requirement for immunosuppression. Similarly, the VX-880 stem cell therapy (Vertex) used a combination of a macroencapsulation device and partial immunosuppression in its early trials; JDRF partnered with Vertex to design the protocol. While VX-880 results showed profound insulin independence in a subset of patients, the immunosuppression issue remains. JDRF is now funding a follow-up study using a device from Beta Bionics that integrates a retrievable encapsulation chamber with a subcutaneous anchoring system—a design that could simplify implantation and removal.

Collaborations That Move the Needle

JDRF’s model relies heavily on public-private partnerships. In 2022, the foundation launched the Bioartificial Pancreas Accelerator (BAPA) program, a consortium that brings together eight biotech companies, four academic centers, and the FDA. This collaborative framework allows sharing of materials, analytical methods, and negative results—often the most valuable data for avoiding dead ends. JDRF also partners with The Helmsley Charitable Trust and the Leona M. and Harry B. Helmsley Charitable Trust to co-fund large animal studies that are too expensive for most academic labs. Such partnerships have already enabled the first successful non-human primate studies of a stem cell-derived islet device combined with a novel oxygen-releasing hydrogel, published in Science Translational Medicine in 2023.

The Road Ahead: Remaining Hurdles

Despite rapid progress, a cure for T1D via a bioartificial pancreas is not yet here. Key challenges include preventing foreign body response (fibrotic encapsulation of the device), ensuring long-term cell function beyond two years, and scaling manufacturing at a cost that health systems can bear. The JDRF’s 2025–2030 Strategic Plan explicitly targets these obstacles. One promising direction is the use of 3D bioprinting to create pre-vascularized scaffolds that integrate with the host circulation upon implantation. JDRF has recently awarded grants to Organovo and Cellink to pursue this technology. Another frontier is the incorporation of real-time wireless sensors that monitor oxygen tension, cell viability, and insulin release within the device, allowing patients and clinicians to intervene early if function declines.

Why JDRF Matters More Than Ever

The type 1 diabetes landscape is crowded with players: pharmaceutical companies developing oral insulin, advanced closed-loop algorithms, and gene therapies. Yet the bioartificial pancreas remains the only approach that restores natural glucose regulation cellularly. JDRF’s sustained, focused investment—over $1 billion since its founding—has de-risked the technology to the point where multiple devices are now in clinical trials. For patients, the hope is that within the next decade, they will no longer need to count every carbohydrate or fear the silence of a hypoglycemic sleep. The path to that reality runs through JDRF’s labs, consortia, and partnerships. To learn more about JDRF’s current funding opportunities and clinical trial updates, visit the official JDRF website or explore ClinicalTrials.gov for active bioartificial pancreas studies. Additional context on encapsulation materials is available via PubMed and the Diabetes Research Institute.

Conclusion

JDRF has positioned itself as the most influential non-governmental force driving the bioartificial pancreas from concept to clinic. By simultaneously tackling cell sourcing, immune protection, oxygenation, and regulatory navigation, the organization is systematically dismantling the barriers that have long stalled this field. While challenges persist, the momentum is undeniable. The bioartificial pancreas is no longer a speculative dream—it is an engineering and biological problem that JDRF is determined to solve. For the millions living with type 1 diabetes, that determination is the closest thing to a lifeline. The next few years will be pivotal, and JDRF will remain at the center of it all.